HOUSTON, May 4, 2023 /PRNewswire/ — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it will report its financial results for the first quarter ended March 31, 2023,…Read More
Moleculin to Report First Quarter Financial Results on May 11 2023 and Host Conference Call and Webcast MarketScreener
